The popularity of Sildenafil initially drove a period of growth for pharma, nevertheless recent shifts present a uncertain outlook for investors. Generic competitors are eroding earnings, and ongoing patent challenges https://flynnbwtn128143.bloggactif.com/42641182/the-blue-pill-and-pharma-a-precarious-bet